— Competitive Grant Program to Offer
Individual Grants of Up to $100,000
per Project —
— Application Period to Run From
Sept. 20, 2024 Through Nov. 30, 2024 —
DUBLIN, Sept. 13,
2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS)
today announced that it will begin accepting applications for its
annual Alkermes Pathways Research Awards® program on
Friday, Sept. 20, 2024. Now in its
seventh year, this competitive grant program is designed to support
the next generation of researchers working on the front lines to
advance our understanding of diseases in the field of neuroscience.
The program will offer grants to early-career investigators who
have demonstrated a commitment to advancing research related to
schizophrenia or bipolar disorder. The application period will run
through Nov. 30, 2024.
"The Alkermes Pathways Research Awards program is one
example of our commitment to the pursuit of great science in the
field of neuroscience. With 25 awards presented since 2018, we are
proud of the impact that the Pathways program has made to support
early-career researchers dedicated to advancing our shared
understanding of complex psychiatric conditions, some of whom have
received grants from the NIH based, in part, on their
Pathways-funded research," said Craig
Hopkinson, M.D., Chief Medical Officer and Executive Vice
President of Research and Development at Alkermes.
The 7th annual Alkermes Pathways Research Awards program will
offer grants in amounts of up to $100,000 per project. To qualify, early-career
investigators must be M.D.s, Ph.D.s, or equivalent, who are within
five years of their initial academic appointment or are current
post-doctoral fellows, and who are affiliated with a medical or
research institution within the United
States. Applicants will be evaluated by an independent
review committee comprised of specialists in psychiatry,
neurobiology, pharmacology, and behavioral science from academic
research centers.
The Alkermes Pathways Research Awards program began in
2018 and has since provided approximately $2.5 million in funding to 25 researchers across
the United States. To date,
research funded by the Pathways program has resulted in multiple
journal publications, oral presentations and posters. Award
recipients have undertaken important, mentor-supported research to
help advance the field of neuroscience. For more information on the
Alkermes Pathways Research Awards program, including full
eligibility criteria and how to apply for the 7th annual edition of
the program, visit www.PathwaysResearchAwards.com.
About Alkermes plc
Alkermes plc is a global
biopharmaceutical company that seeks to develop innovative
medicines in the field of neuroscience. The company has a portfolio
of proprietary commercial products for the treatment of alcohol
dependence, opioid dependence, schizophrenia and bipolar I
disorder, and a pipeline of clinical and preclinical candidates in
development for neurological disorders, including narcolepsy.
Headquartered in Ireland, Alkermes
also has a corporate office and research and development center in
Massachusetts and a manufacturing
facility in Ohio. For more
information, please visit Alkermes' website at
www.alkermes.com.
Alkermes Pathways Research Awards® is a registered
service mark of Alkermes, Inc. The Alkermes Pathways Research
Awards logo is a service mark of Alkermes, Inc.
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781
609 6377
For Media: Gretchen Murphy, +1
781 609 6419
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alkermes-announces-launch-of-7th-annual-alkermes-pathways-research-awards-program-302247361.html
SOURCE Alkermes plc